Last reviewed · How we verify
NCT02973607: CRIB-DONOR II
Effects of a Reduction in Renal Function on Cardiovascular Structure and Function
trial testing Nephrectomy in Chronic Kidney Disease in 95 participants. Completed in 31 July 2020.
20 March 2020
Quick facts
| Lead sponsor | University Hospital Birmingham NHS Foundation Trust |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 95 |
| Start date | 23 May 2017 |
| Primary completion | 20 March 2020 |
| Estimated completion | 31 July 2020 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Nephrectomy
Conditions studied
- Chronic Kidney Disease — all drugs for Chronic Kidney Disease →
- Hypertrophy, Left Ventricular — all drugs for Hypertrophy, Left Ventricular →
- Hypertension — all drugs for Hypertension →
Sponsor
University Hospital Birmingham NHS Foundation Trust
Who can join
Adults 18 to 80, any sex, with Chronic Kidney Disease or Hypertrophy, Left Ventricular. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Chronic kidney disease (CKD) is present in 1 in 7 of the population and confers a high risk of cardiovascular disease. The pathophysiology of cardiovascular disease in CKD is poorly understood because CKD is always accompanied by confounding factors including the underlying disease process (e.g. diabetes mellitus, systemic vasculitis) and the consequences of CKD including hypertension, anaemia and inflammation. Nephrectomy in kidney donors causes a 30% reduction in renal function providing an ideal study population to measure prospectively the effects of reduced kidney function on the cardiovascular system. The CRIB-Donor study (ClinicalTrials.gov Identifier:NCT01028703) demonstrated adverse effects on cardiovascular structure and function at 12 months compared to controls including an increase in left ventricular mass. This proposal will measure the changes in cardiovascular structure and function, cardiovascular age and biochemical changes at 5 years providing information on the long term effects of reduced renal function.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Cardiovascular Effects of Unilateral Nephrectomy in Living Kidney Donors at 5 Years.
Price AM, Moody WE, Stoll VM, Vijapurapu R, et al · · 2021 · cited 14× · PMID 33550822 · DOI 10.1161/hypertensionaha.120.15398
Verify or expand the search:
- PubMed search for NCT02973607
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Nephrectomy
Trials testing the same drug.
- NCT07226544 — Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer · Phase 2 · not yet recruiting
- NCT07516366 — Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell R · Phase 2 · not yet recruiting
- NCT06401330 — A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) · Phase 3 · recruiting
- NCT04402749 — The Incidence of Pulmonary Embolism During Nephrectomy · completed
- NCT04326517 — Factors Associated To Intensive Care Admission And Mortality In Patients With Emphysematous Pyelonephritis · unknown
Other recruiting trials for Chronic Kidney Disease
Currently open trials in the same condition.
- NCT07469540 — Effects of an Aerobic Exercise Program on Cardiovascular Risk in Patients With Chronic Kidney Disease or Rheumatoid Arth · NA · recruiting
- NCT07169422 — Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care · NA · recruiting
- NCT07481526 — A Prospecitve Multicenter, Observational Registry Study · recruiting
- NCT07450820 — OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD · recruiting
- NCT07107945 — A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease · Phase 3 · recruiting
Other University Hospital Birmingham NHS Foundation Trust trials
Trials by the same sponsor.
- NCT04916704 — Subclinical Cytomegalovirus Reactivation in Acute ANCA-associated Vasculitis · active not recruiting
- NCT05376228 — A Systems Biology Approach for Identification of Host and Microbial Mechanisms and Druggable Targets for the Treatment o · unknown
- NCT04727268 — Genotype-phenotype Correlation in Junctional Epidermolysis Bullosa · unknown
- NCT05405907 — Evaluation of the Haemostatic Agent Purabond in ENT TORS · completed
- NCT04902352 — The DISSECT Study: Effect of Peri-aDventItial SMA diSsECtion on Margin sTatus During Pancreaticoduodenectomy for Resecta · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02973607 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital Birmingham NHS Foundation Trust
- Last refreshed: 5 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02973607.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing